Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MRNA

Moderna, Inc.

Healthcare | Biotechnology
$142.74 -6.13 (-4.12%) as of 2026-09-04 15:46 UTC
Market Cap$59.4B
EPS (TTM)$-7.26

Moderna, Inc. (NASDAQ: MRNA) is a $59.4B biotechnology company trading at $142.74 (−4.1% today). Figures from SEC EDGAR and market feeds; updated 2026-09-04 15:46 UTC.

52-Week Range
Low $43.68High $176.66

What Moderna, Inc. does

Moderna is a company that develops medicines using mRNA technology, which enables cells to produce specific proteins for treating and preventing diseases. The company currently sells three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (an RSV vaccine), generating total revenue largely from COVID vaccine sales. Beyond these products, Moderna is advancing a pipeline of candidates in oncology, rare disease, and infectious disease, including a personalized cancer therapy developed with Merck, seasonal flu vaccine candidates, and treatments for rare metabolic disorders.

Summarized from Moderna, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$142.74
Change (1D)-6.13 (-4.12%)
Market cap$59.4B
52-week range$43.68 – $176.66
Valuation
EPS (TTM)$-7.26
Price/book6.87×
Debt/equity0.07
Returns
52-week return+226.8%

Revenue, margins & earnings

FY2021 Net income: $12.2BFY2021 Taxes & interest: $1.09BFY2021 Operating costs: $5.17B$18.5BFY2021FY2022 Net income: $8.36BFY2022 Taxes & interest: $1.06BFY2022 Operating costs: $9.84B$19.3BFY2022FY2023: net loss $4.71B on revenue $6.85B$6.85BFY2023FY2024: net loss $3.56B on revenue $3.24B$3.24BFY2024FY2025: net loss $2.82B on revenue $1.94B$1.94BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-03
  • 2026-09-03Klinger Shannon ThymeChief Legal OfficerM3,471$107.5K
  • 2026-09-03Klinger Shannon ThymeChief Legal OfficerSELL-3,471$485.8K
  • 2026-09-03Mock James MChief Financial OfficerM2,475—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Moderna, Inc. do?

Moderna is a company that develops medicines using mRNA technology, which enables cells to produce specific proteins for treating and preventing diseases.

What is MRNA's valuation?

MRNA trades at $142.74, as of 2026-09-04.

When did MRNA last file with the SEC?

Moderna, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-07-31. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-04 15:46 UTC. This page is also available as JSON at /api/data?ticker=MRNA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MRNA and 5,000+ tickers.

Create a free account — keep MRNA
For your agent
GET /api/data?ticker=MRNA

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt